Application of lovastatin or pharmaceutically acceptable salt thereof in preparation of drugs for treating cerebral arteriovenous malformation

A technology of arteriovenous malformation and lovastatin, applied in the field of medicine, can solve the problems of increasing bleeding or ischemia or even life risk of patients, lack of core management tools for continuous quality evaluation, and lack of key technical details and specifications, so as to improve hemodynamics The effect of improving the study, solving the long-term bleeding risk, and reducing the disability rate and mortality rate

Inactive Publication Date: 2020-08-25
BEIJING TIANTAN HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Misselection of hybrid surgery treatment may lead to disability and death of patients and greater waste of medical resources
The following aspects of hybrid surgery need to be studied urgently: 1. There is no indication for hybrid surgery supported by evidence-based medicine; 2. There is a lack of key technical details and specifications, and there is a lack of core management tools for continuous quality evaluation and continuous promotion, which affects the treatment effect; 3. Hybrid surgery During the course of treatment, there are various options for anticoagulant regimens, and mistakes in the choice of regimens will increase the risk of bleeding or ischemia and even life of patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of lovastatin or pharmaceutically acceptable salt thereof in preparation of drugs for treating cerebral arteriovenous malformation
  • Application of lovastatin or pharmaceutically acceptable salt thereof in preparation of drugs for treating cerebral arteriovenous malformation
  • Application of lovastatin or pharmaceutically acceptable salt thereof in preparation of drugs for treating cerebral arteriovenous malformation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] (1) Whole-exome sequencing revealed somatic mutations in sporadic cerebral arteriovenous malformations

[0047] Whole-exome sequencing of cerebral arteriovenous malformation (AVM) surgical specimens and their paired peripheral blood found that about 36% of them had KRAS gene mutations (such as Figure 1A shown). In order to improve the sensitivity of capturing mutations and clarify which cells in the vascular structure are mutated, we further collected specimens, and extracted vascular endothelial cells and vascular wall cells in abnormal specimens for micro-cell whole exome sequencing. The results showed that KRAS mutations were concentrated in endothelial cells, and KRAS mutations were present in about 73% of cases (eg, Figure 1B shown). KRAS gene is an important regulatory gene, which plays an important regulatory role in the signal transduction pathway of tumor cell growth and angiogenesis.

[0048] (2) Endothelial-mesenchymal transition exists in brain arteriove...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of medicines, and particularly relates to a new application of lovastatin. The invention provides an application of the lovastatin or pharmaceutically acceptable salt thereof in preparation of drugs for treating cerebral arteriovenous malformation. The lovastatin or the pharmaceutically acceptable salt thereof is used for inhibiting interstitial transformation ofendothelial cells in the cerebral arteriovenous malformation and improving the stability of the endothelial cells in a focus, so that the barrier effect of the endothelial cells in the malformed blood vessels is protected, and the possibility of rupture hemorrhage caused by the cerebral arteriovenous malformation is reduced. Therefore, the lovastatin or the pharmaceutically acceptable salt thereof is used to treat and/or improve the cerebral arteriovenous malformation.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to a new application of lovastatin. Background technique [0002] The pathogenesis of intracranial arteriovenous malformation (AVM) is still unclear, and it is generally considered to be a congenital cerebrovascular disease, which is more common in cerebrovascular surgery. It can exist in various parts above and below the tentorium, and it is mostly wedge-shaped, with its tip pointing to the lateral ventricle. The main pathological change is the lack of capillary bed connection between some arteries and veins in the brain, so that some cerebral arteries and veins are directly connected to form cerebral arteriovenous fistula malformation, resulting in cerebral hemodynamic disorders. Clinically, the main manifestations are repeated intracranial hemorrhage, partial or generalized seizures, transient ischemic attack (TIA), and progressive and focal neurological deficits. [0003] A...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/366A61P9/00A61P25/00
CPCA61K31/366A61P9/00A61P25/00
Inventor 霍然曹勇李昊
Owner BEIJING TIANTAN HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap